Lipitor Market analysis and forecasts Report 2007-2012, 2017 & 2023

March 19, 2009 - PRLog -- Report Details
In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol.

However, as Lipitor’s blockbuster revenue is seriously threatened by imminent patent expiration in some of the drug’s largest markets such as the US, Japan and the UK, there is significant unrest between Pfizer’s key stakeholders about the future of the drug. Principally, amongst the heightened Lipitor topics are the imminent exposure of the $1 billion annual drug sales or more, as well as the fast expanding generic market in which India’s Ranbaxy is a dominant force.

What questions does the report answer?

• Has the success of Pfizer’s Lipitor been overstated?
• Did Pfizer create a monster in Lipitor?
• Have Lipitor sales redefined the bounds that pharmaceutical margins can now reach?
• How imminent is Lipitor patent expiration?
• Which key markets will suffer the consequence of Lipitor expiry?
• Is Ranbaxy ready for generic Lipitor?
• Do the fast developing markets, CEE and the Latin America segment hold the key to future sales after Lipitor’s patent expiration?
• Is Lipitor a victim of the struggling Blockbuster Model?
• What is next for Lipitor?

As Pfizer’s Lipitor struggles to fend off the immediate entry of Ranbaxy’s generic Lipitor, in key markets, the legal challenges surrounding the number one drug have set a new benchmark for pharmaceutical companies protecting branded products. Industry observers including Visiongain predicts that Pfizer’s crises are far from over, as the high revenue streams of Lipitor will experience significant challenges before the commencement of the next decade.

Moreover, Pfizer’s lack of success to replace Lipitor with Torcetrapib has escalated the company’s near-term battles besides the ever-tighter regulatory hurdles, reduced R&D efficiency and increased competition, creating formidable therapeutic challenges as healthcare payers influence pricing. Nevertheless, there are strong drivers of growth including unmet therapeutic needs, the rising incidence of multiple diseases, ageing populations, the rising living standards and fast-developing geographical markets. The future of Lipitor is therefore vitally important to Pfizer, especially in this uncertain period of economic changes and pressures.

This report includes detailed five-year forecasts over the period 2008-2013, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This unique in-depth management report examines the future prospects for Lipitor from 2008-2023. It delivers direct to you future sales forecasts for leading Lipitor in all seven major markets (7MM). This detailed report highlights the most compelling must know issues- Lipitor’s patent contention by Pfizer in both 7MM and other markets in order to block Ranbaxy’s immediate penetration of generic Lipitor. In light of healthcare drug bills increasing exponentially, generic Lipitor will be welcomed by managed care organisations (MCO) and further widen the generic revenue margins, visiongain concludes. This report also tackles Lipitor’s significant developments, potential opportunities on the market and important contemporary matters, especially commercial drivers and restraints.

Companies Listed
Abant Izzet Baysal University
Abbott
Actavis
Aegerion Pharmaceuticals
American College of Clinical Pharmacy
American Heart Association
and Cardiovascular Health
Apotex
ASKA Pharmaceutical
Astellas
AstraZeneca
Basic GmbH
Beside Health
Beth Israel Deaconess Medical Centre
Biovail
Boston University
Bristol Myers Squibb
Buddhist Tzu Chi General Hospital
Canadian Heart Research Centre
Cardiovascular Institute and Fuwai Hospital
Chiesi
Children's Hospital of Philadelphia
Children's Mercy Hospital Kansas City
Cipla
CNAM (Conservatoire National des Arts et Métiers)
Cobalt Pharmaceuticals
Daiichi Sankyo
Damon Runyon Cancer Research Foundation
DiObex
Emory University
FDA Office of Orphan Products Development
First Horizon
Gedeon Richter
GlaxoSmithKline
Global Pharmaceuticals
Hartford Hospital,CT USA
Hospital de Clinicas de Porto Alegre
Japan Foundation for the Promotion of International Medical Research Cooperation
Kaken
Korea University Anam Hospital
Kos Pharmaceuticals
LifeCycle Pharma
Lupin
M.D. Anderson Cancer Centre
Maine Centre for Lipids
Masaryk University
Mayo Clinic
McGill University Health Centre
Medical College of Wisconsin
Medical Research Council
Medical University of South Carolina
Memorial Sloan-Kettering
Merck & Co
Merck KGaA
Ministry of Science and Higher Education, Poland
MSD
National Cancer Institute (NCI)
National Centre for Research Resources (NCRR)
National Heart, Lung and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Disease (NIAID)
National Institutes of Health (NIH)
National Science Council, Taiwan
National Taiwan University Hospital
New York University School of Medicine
NHS Greater Glasgow and Clyde
Nobel
Novartis
Ontario Association of Optometrists
Ontario Thoracic Society
OrbusNeich
Par Pharmaceuticals
Park-Davis
Penn State University
Pfizer
Pharma Nord
Queen's University
Queen's University
R&D Cardiologie UMC Utrecht
Radboud University
Ranbaxy
Rikshospitalet-Radiumhospitalet
Roche
Samsung Medical Centre
Sanofi-Aventis
Schering Plough
Sciele
Servier
Seven Seas
Shenyang Northern Hospital
Shenyang Northern Hospital
Silesian School of Medicine
SkyePharm
Solvay
St Vincent's University Hospital, Ireland
St. Michael's Hospital, Toronto
Stanford University
Sun Pharma
Tanabe
Teijan
Teofarma
Teva Pharmaceuticals
The Centre for Rheumatic Disease Allergy, & Immunology Saint Luke's Hospital
The Cleveland Clinic
The Gustavus and Louise Pfeiffer Research Foundation
The Hospital of Vestfold
The Netherlands Organisation for Health Research and Development
The Physicians' Services Incorporated Foundation
Toronto Ophthalmological Society
Università degli Studi dell'Insubria
University Hospital, Brest
University Hospital, Motol
University of Calgary Heart and Stroke Foundation of Ontario
University of California
University of Campinas
University of Chicago
University of Florida
University of Glasgow
University of North Carolina
University of Oslo
University of Oslo School of Pharmacy
University of Toronto
University of Wisconsin, Madison
VU University Medical Centre
Warner-Lambert
WellPoint
Yokohama City University Medical Centre

Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=272
Or http://www.visiongain.com

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.